Recent data suggest that the orexigenic peptide ghrelin and liver-expressed antimicrobial peptide 2 (LEAP2) have opposing effects on food intake regulation. Although circulating ghrelin is decreased in obesity, peripheral ghrelin administration does not induce food intake in obese mice. Limited information is available on ghrelin resistance in relation to LEAP2. In this study, the interplay between ghrelin and LEAP2 in obesity induced by a high-fat (HF) diet in mice was studied. First, the progression of obesity and intolerance to glucose together with plasma levels of active and total ghrelin, leptin, as well as liver LEAP2 mRNA expression at different time points of HF diet feeding was examined. In addition, the impact of switch from a HF diet to a standard diet on plasma ghrelin and LEAP2 production was studied. Second, sensitivity to the stable ghrelin analogue [Dpr3]Ghrelin or our novel LEAP2 analogue palm-LEAP2(1-14) during the progression of HF diet-induced obesity and after the switch for standard diet was investigated. Food intake was monitored after acute subcutaneous administration. HF diet feeding decreased both active and total plasma ghrelin and increased liver LEAP2 mRNA expression along with intolerance to glucose and the switch to a standard diet normalized liver LEAP2 mRNA expression and plasma level of active ghrelin, but not of total ghrelin. Additionally, our study demonstrates that a HF diet causes resistance to [Dpr3]Ghrelin, reversible by switch to St diet, followed by resistance to palm-LEAP2(1-14). Further studies are needed to determine the long-term effects of LEAP2 analogues on obesity-related ghrelin resistance.

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Praha 6 Czech Republic

See more in PubMed

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660. doi: 10.1038/45230. PubMed DOI

Cowley MA, Smith RG, Diano S, Tschop M, Pronchuk N, Grove KL, Strasburger CJ, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–661. doi: 10.1016/S0896-6273(03)00063-1. PubMed DOI

Uriarte M, De Francesco PN, Fernandez G, Castrogiovanni D, D’Arcangelo M, Imbernon M, Cantel S, et al. Circulating ghrelin crosses the blood-cerebrospinal fluid barrier via growth hormone secretagogue receptor dependent and independent mechanisms. Mol Cell Endocrinol. 2021;538:111449. doi: 10.1016/j.mce.2021.111449. PubMed DOI

Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist. Mol Endocrinol. 2003;17:2201–2210. doi: 10.1210/me.2003-0069. PubMed DOI

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, et al. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metab. 2018;27:461–469.e6. doi: 10.1016/j.cmet.2017.10.016. PubMed DOI

M’Kadmi C, Cabral A, Barrile F, Giribaldi J, Cantel S, Damian M, Mary S, et al. N-Terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor. J Med Chem. 2019;62:965–973. doi: 10.1021/acs.jmedchem.8b01644. PubMed DOI

Hola L, Zelezna B, Karnosova A, Kunes J, Fehrentz JA, Denoyelle S, Cantel S, et al. A novel truncated liver enriched antimicrobial peptide-2 palmitoylated at its N-terminal antagonizes effects of ghrelin. J Pharmacol Exp Ther. 2022;383:129–136. doi: 10.1124/jpet.122.001322. PubMed DOI

Shankar K, Metzger NP, Singh O, Mani BK, Osborne-Lawrence S, Varshney S, Gupta D, et al. LEAP2 deletion in mice enhances ghrelin’s actions as an orexigen and growth hormone secretagogue. Mol Metab. 2021;53:101327. doi: 10.1016/j.molmet.2021.101327. PubMed DOI PMC

Hagemann CA, Jensen MS, Holm S, Gasbjerg LS, Byberg S, Skov-Jeppesen K, Hartmann B, et al. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Rep Med. 2022;3:100582. doi: 10.1016/j.xcrm.2022.100582. PubMed DOI PMC

Mani BK, Puzziferri N, He Z, Rodriguez JA, Osborne-Lawrence S, Metzger NP, Chhina N, et al. LEAP2 changes with body mass and food intake in humans and mice. J Clin Invest. 2019;129:3909–3923. doi: 10.1172/JCI125332. PubMed DOI PMC

Holm S, Husted AS, Skov LJ, Morville TH, Hagemann CA, Jorsal T, Dall M, et al. Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2. Endocrinology. 2022;163:bqac038. doi: 10.1210/endocr/bqac038. PubMed DOI PMC

Gradel AKJ, Holm SK, Byberg S, Merkestein M, Hogendorf WFJ, Lund ML, Buijink JA, et al. The dietary regulation of LEAP2 depends on meal composition in mice. FASEB J. 2023;37:e22923. doi: 10.1096/fj.202201828R. PubMed DOI

Garces MF, Buell-Acosta JD, Angel-Muller E, Parada-Banos AJ, Acosta-Alvarez J, Saavedra-Lopez HF, Franco-Vega R, et al. Study of the Ghrelin/LEAP-2 Ratio in Humans and Rats during Different Phases of Pregnancy. Int J Mol Sci. 2022;23:9514. doi: 10.3390/ijms23179514. PubMed DOI PMC

Banks WA, Burney BO, Robinson SM. Effects of triglycerides, obesity, and starvation on ghrelin transport across the blood-brain barrier. Peptides. 2008;29:2061–2065. doi: 10.1016/j.peptides.2008.07.001. PubMed DOI PMC

Perreault M, Istrate N, Wang L, Nichols AJ, Tozzo E, Stricker-Krongrad A. Resistance to the orexigenic effect of ghrelin in dietary-induced obesity in mice: reversal upon weight loss. Int J Obes Relat Metab Disord. 2004;28:879–885. doi: 10.1038/sj.ijo.0802640. PubMed DOI

English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002;87:2984. doi: 10.1210/jcem.87.6.8738. PubMed DOI

Martin NM, Small CJ, Sajedi A, Patterson M, Ghatei MA, Bloom SR. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord. 2004;28:886–893. doi: 10.1038/sj.ijo.0802646. PubMed DOI

Gardiner JV, Campbell D, Patterson M, Kent A, Ghatei MA, Bloom SR, Bewick GA. The hyperphagic effect of ghrelin is inhibited in mice by a diet high in fat. Gastroenterology. 2010;138:2468–2476e1. doi: 10.1053/j.gastro.2010.02.012. PubMed DOI

Briggs DI, Enriori PJ, Lemus MB, Cowley MA, Andrews ZB. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. Endocrinology. 2010;151:4745–4755. doi: 10.1210/en.2010-0556. PubMed DOI

Briggs DI, Andrews ZB. Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology. 2011;93:48–57. doi: 10.1159/000322589. PubMed DOI

Briggs DI, Lockie SH, Wu Q, Lemus MB, Stark R, Andrews ZB. Calorie-restricted weight loss reverses high-fat diet-induced ghrelin resistance, which contributes to rebound weight gain in a ghrelin-dependent manner. Endocrinology. 2013;154:709–717. doi: 10.1210/en.2012-1421. PubMed DOI

Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem. 2000;43:4370–4376. doi: 10.1021/jm0001727. PubMed DOI

Popelova A, Kakonova A, Hruba L, Kunes J, Maletinska L, Zelezna B. Potential neuroprotective and anti-apoptotic properties of a long-lasting stable analog of ghrelin: an in vitro study using SH-SY5Y cells. Physiol Res. 2018;67:339–346. doi: 10.33549/physiolres.933761. PubMed DOI

Holubova M, Blechova M, Kakonova A, Kunes J, Zelezna B, Maletinska L. In Vitro and In Vivo Characterization of Novel Stable Peptidic Ghrelin Analogs: Beneficial Effects in the Settings of Lipopolysaccharide-Induced Anorexia in Mice. J Pharmacol Exp Ther. 2018;366:422–432. doi: 10.1124/jpet.118.249086. PubMed DOI

Maletinska L, Pychova M, Holubova M, Blechova M, Demianova Z, Elbert T, Zelezna B. Characterization of new stable ghrelin analogs with prolonged orexigenic potency. J Pharmacol Exp Ther. 2012;340:781–786. doi: 10.1124/jpet.111.185371. PubMed DOI

Maletinska L, Nagelova V, Ticha A, Zemenova J, Pirnik Z, Holubova M, Spolcova A, et al. Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration. Int J Obes (Lond) 2015;39:986–993. doi: 10.1038/ijo.2015.28. PubMed DOI

Holubova M, Spolcova A, Demianova Z, Sykora D, Fehrentz JA, Martinez J, Stofkova A, et al. Ghrelin agonist JMV 1843 increases food intake, body weight and expression of orexigenic neuropeptides in mice. Physiol Res. 2013;62:435–444. doi: 10.33549/physiolres.932488. PubMed DOI

Prazienkova V, Funda J, Pirnik Z, Karnosova A, Hruba L, Korinkova L, Neprasova B, et al. GPR10 gene deletion in mice increases basal neuronal activity, disturbs insulin sensitivity and alters lipid homeostasis. Gene. 2021;774:145427. doi: 10.1016/j.gene.2021.145427. PubMed DOI

Schalla MA, Stengel A. Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges. Curr Diab Rep. 2019;19:102. doi: 10.1007/s11892-019-1211-9. PubMed DOI

Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW. Common structural basis for constitutive activity of the ghrelin receptor family. J Biol Chem. 2004;279:53806–53817. doi: 10.1074/jbc.M407676200. PubMed DOI

Cummings DE, Purnell JQ, Frayo RS, Ma MK, Dellinger EP, Weigle DS. Plasma ghrelin levels are markedly decreased after gastric bypass surgery in humans. Obes Res. 2001;9:73s–73s.

Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–709. doi: 10.2337/diabetes.50.4.707. PubMed DOI

Briggs DI, Lockie SH, Benzler J, Wu Q, Stark R, Reichenbach A, Hoy AJ, et al. Evidence that diet-induced hyperleptinemia, but not hypothalamic gliosis, causes ghrelin resistance in NPY/AgRP neurons of male mice. Endocrinology. 2014;155:2411–2422. doi: 10.1210/en.2013-1861. PubMed DOI

Andrews ZB. The next big LEAP2 understanding ghrelin function. J Clin Invest. 2019;129:3542–3544. doi: 10.1172/JCI131023. PubMed DOI PMC

Islam MN, Mita Y, Maruyama K, Tanida R, Zhang W, Sakoda H, Nakazato M. Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents. J Endocrinol. 2020;244:13–23. doi: 10.1530/JOE-19-0102. PubMed DOI PMC

Reynolds KA, Boudoures AL, Chi MM, Wang Q, Moley KH. Adverse effects of obesity and/or high-fat diet on oocyte quality and metabolism are not reversible with resumption of regular diet in mice. Reprod Fertil Dev. 2015;27:716–724. doi: 10.1071/RD14251. PubMed DOI PMC

Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;22:291–299. doi: 10.1111/j.1365-2036.2005.02562.x. PubMed DOI

Francisco V, Tovar S, Conde J, Pino J, Mera A, Lago F, Gonzalez-Gay MA, et al. Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis. Nutrients. 2020;12:1006. doi: 10.3390/nu12041006. PubMed DOI PMC

Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010;2010:289645. doi: 10.1155/2010/289645. PubMed DOI PMC

Peracchi M, Bardella MT, Caprioli F, Massironi S, Conte D, Valenti L, Ronchi C, et al. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut. 2006;55:432–433. doi: 10.1136/gut.2005.079483. PubMed DOI PMC

Okamatsu Y, Matsuda K, Hiramoto I, Tani H, Kimura K, Yada Y, Kakuma T, et al. Ghrelin and leptin modulate immunity and liver function in overweight children. Pediatr Int. 2009;51:9–13. doi: 10.1111/j.1442-200X.2008.02647.x. PubMed DOI

Machado MV, Coutinho J, Carepa F, Costa A, Proenca H, Cortez-Pinto H. How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2012;24:1166–1172. doi: 10.1097/MEG.0b013e32835609b0. PubMed DOI

Briggs DI, Lemus MB, Kua E, Andrews ZB. Diet-induced obesity attenuates fasting-induced hyperphagia. J Neuroendocrinol. 2011;23:620–626. doi: 10.1111/j.1365-2826.2011.02148.x. PubMed DOI

Kohsaka A, Laposky AD, Ramsey KM, Estrada C, Joshu C, Kobayashi Y, Turek FW, et al. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab. 2007;6:414–421. doi: 10.1016/j.cmet.2007.09.006. PubMed DOI

Naznin F, Toshinai K, Waise TM, NamKoong C, Md Moin AS, Sakoda H, Nakazato M. Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation. J Endocrinol. 2015;226:81–92. doi: 10.1530/JOE-15-0139. PubMed DOI PMC